RCM
FTH

RA Capital Management’s Faeth Therapeutics FTH Stock Holding History

RA Capital Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,176
Closed -$1.06M – 80
2022
Q3 		$1.06M Sell
34,176
-2,001
-6% -$78.6K 0.02% 78
2022
Q2 		$1.64M Buy
+36,177
New +$1.36M 0.04% 84

Other funds holding FTH

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RA Capital Management's FTH Position: Q4 2022 in Review

RA Capital Management sold out of Faeth Therapeutics (FTH) in Q4 2022, closing a stake of 34,176 shares — an estimated $1.06M sold.

RA Capital Management first reported a position in FTH in Q2 2022 and held it in 2 quarters. The position peaked at $1.64M in Q2 2022. 26 funds tracked by Wall St. Rank hold FTH as of Q4 2022.

  • RA Capital Management reported no remaining Faeth Therapeutics position as of Q4 2022 after selling out during the quarter.
  • RA Capital Management sold 34,176 Faeth Therapeutics shares in Q4 2022, an estimated $1.06M.
  • RA Capital Management first reported a position in Faeth Therapeutics in Q2 2022 and held it in 2 quarters.
  • RA Capital Management's Faeth Therapeutics position peaked at $1.64M in Q2 2022.
  • 26 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q4 2022.

Based on RA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.